Form 4: Ironwood Pharmaceuticals Director Alexander Denner Receives Equity Grant as Compensation

Alexander J. Denner, a Director and 10% owner of Ironwood Pharmaceuticals Inc. (IRWD), has reported the acquisition of 24,193 shares of Class A Common Stock as part of the company's non-employee director compensation policy.

Summary

• Alexander J. Denner, who serves as a Director and 10% owner of Ironwood Pharmaceuticals Inc. (IRWD), reported a transaction on June 13, 2025.
• The transaction involved the acquisition of 24,193 shares of Class A Common Stock.
• These shares were issued at a price of $0, pursuant to the company's Second Amended and Restated Non-employee Director Compensation Policy, which became effective on January 1, 2024.
• Following this transaction, Dr. Denner directly beneficially owns 235,962 shares of Class A Common Stock.
• Additionally, Dr. Denner indirectly beneficially owns 16,390,000 shares through Sarissa Capital Management LP and its associated funds, where he serves as Chief Investment Officer and control party.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates an increase in insider ownership, albeit through a compensation grant rather than an open market purchase, which is a standard practice for director remuneration.

Positives

• The acquisition of 24,193 shares increases insider ownership, which can signal alignment of interests between management/directors and shareholders.
• The shares were issued as part of a compensation policy, indicating a structured approach to director remuneration.

Risks

• The document does not explicitly mention risks, but reliance on equity-based compensation can expose directors to stock price volatility.

Future Outlook

This document, an SEC Form 4, does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• Alexander J. Denner's indirect beneficial ownership of 16,390,000 shares is through Sarissa Capital Management LP and Sarissa Funds, where he is the Chief Investment Officer and control party. This represents a related party relationship.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, potentially boosting investor confidence due to perceived alignment of interests.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, SEC Form 4, Insider Transaction, Alexander Denner, Director Compensation, Equity Grant, Sarissa Capital Management, Beneficial Ownership